Antidepressants increase the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . D oxepin hydrochloride is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )] .
Doxepin hydrochloride is indicated for the treatment of major depressive disorder (MDD) in adults.
Prior to initiating treatment with doxepin hydrochloride, screen patients for a personal or family history of bipolar disorder, mania, or hypomania [see Warnings and Precautions ( 5.5 )] . The recommended starting oral dosage for doxepin hydrochloride is 25 mg three times daily or 75 mg once daily. The recommended target total oral dosage range for doxepin hydrochloride is between 75 mg/day and 150 mg/day (may be ...
How Supplied Doxepin Hydrochloride Oral Solution USP (Concentrate). Each mL of oral solution contains 10 mg of doxepin as a clear, colorless solution and is supplied in 120 mL bottles (NDC 54838-512-40) with an accompanying dropper calibrated at 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg. Store Doxepin Hydrochloride Oral Solution USP at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled...
www.fda.gov/medwatchwww.fda.gov/CYPandTransporterInteractingDrugs
womensmentalhealth.org/clinical-and-research-
www.lannett.comwomensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressantsAntidepressants increase the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1)]. Doxepin hydrochloride is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4)].
Doxepin hydrochloride is indicated for the treatment of major depressive disorder (MDD) in adults.
Prior to initiating treatment with doxepin hydrochloride, screen patients for a personal or family history of bipolar disorder, mania, or hypomania [see Warnings and Precautions ( 5.5 )].
The recommended starting oral dosage for doxepin hydrochloride is 25 mg three times daily or 75 mg once daily. The recommended target total oral dosage range for doxepin hydrochloride is between 75 mg/day and 150 mg/day (may be given once daily or in divided doses). The maximum recommended oral dosage for doxepin hydrochloride is 100 mg three times daily.
Wait at least 14 days after discontinuation of a monoamine oxidase inhibitor (MAOI) before initiating therapy with doxepin hydrochloride [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), and Drug Interactions ( 7 )].
Wait at least 14 days after discontinuation of doxepin hydrochloride before initiating therapy with an MAOI [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), and Drug Interactions ( 7 )].
If anticholinergic effects (e.g., dry mouth, blurred vision, constipation) develop, reduce the doxepin hydrochloride dosage [see Adverse Reactions ( 6.1 )].
Reduce the doxepin hydrochloride dosage based on doxepin plasma concentrations when used concomitantly with strong CYP2D6 inhibitors [see Drug Interactions ( 7 )].
Reduce the doxepin hydrochloride dosage based on doxepin plasma concentrations in patients who are known CYP2D6 and CYP2C19 poor metabolizers [see Use in Specific Populations ( 8.7 )].
When discontinuing doxepin hydrochloride, gradually reduce the dosage until discontinued [see Adverse Reactions ( 6 )].
Recommended preparation instructions for the Doxepin Hydrochloride Oral Solution are as follows:
Oral solution: Each mL of oral solution contains 10 mg of doxepin as a clear, colorless solution for dilution prior to administration [see Dosage and Administration ( 2.8 )]. Supplied as a 120 mL bottle with accompanying calibrated dropper with 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg markings.
Doxepin hydrochloride is contraindicated in patients:
In pooled analyses of placebo-controlled trials of antidepressant drugs including tricyclic antidepressants and other antidepressant classes that included approximately 77,000 adult patients and 4,500 pediatric patients (doxepin hydrochloride is not approved for use in pediatric patients), the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1,000 patients treated are provided in Table 1.
Table 1: Risk Differences of the Number of Patients of Suicidal Thoughts and Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients
| Age Range | Drug-Placebo Difference in Number of Patients of Suicidal Thoughts or Behaviors per 1,000 Patients Treated |
| Increases Compared to Placebo | |
| < 18 years old | 14 additional patients |
| 18-24 years old | 5 additional patients |
| Decreases Compared to Placebo | |
| 25-64 years old | 1 fewer patient |
| ≥ 65 years old | 6 fewer patients |
It is unknown whether the risk of suicidal thoughts and behaviors in pediatric and young adults extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression.
Monitor all doxepin hydrochloride-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of doxepin hydrochloride therapy, and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing doxepin hydrochloride, in patients who are experiencing emergent suicidal thoughts or behaviors.
Tricyclic antidepressants, including doxepin hydrochloride, can precipitate serotonin syndrome, a potentially life-threatening condition. This risk is increased with concomitant use of other serotonergic drugs (e.g., other tricyclic antidepressants, SSRIs, serotonin norepinephrine reuptake inhibitors, triptans, tetracyclic antidepressants, opioids), lithium, tryptophan, buspirone, and St. John’s Wort) and with drugs that impair metabolism of serotonin (e.g., MAOIs intended to treat psychiatric disorders and others, such as linezolid or intravenous methylene blue) [see Drug Interactions ( 7 )].
Serotonin syndrome symptoms may include mental status changes (e.g., confusion, agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia, diaphoresis, and flushing), neuromuscular abnormalities (e.g., tremor, rigidity, clonus, and hyperreflexia), seizures and gastrointestinal signs and symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.
The concomitant use of doxepin hydrochloride with MAOIs is contraindicated. The use of doxepin hydrochloride within 14 days of discontinuing treatment with an MAOI intended to treat psychiatric disorders is contraindicated. Starting doxepin hydrochloride in a patient who is being treated with an MAOI such as linezolid or intravenous methylene blue is contraindicated. No reports involved the administration of methylene blue by other routes (such as oral or local tissue injection). If it is necessary to initiate treatment with a MAOI such as linezolid or intravenous methylene blue in a patient taking doxepin hydrochloride, discontinue doxepin hydrochloride before initiating treatment with the MAOI [see Dosage and Administration ( 2.4 ) and Drug Interactions ( 7 )].
Monitor all patients taking doxepin hydrochloride for the emergence of serotonin syndrome. Discontinue doxepin hydrochloride treatment and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of doxepin hydrochloride with other serotonergic drugs (besides MAOIs which are contraindicated) is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.
The pupillary dilation that occurs following use of many antidepressant drugs including doxepin hydrochloride may trigger an angle closure glaucoma attack in a patient with anatomically narrow angles who does not have a patent iridectomy. Patients may wish to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.
Doxepin hydrochloride is contraindicated in patients with glaucoma. Avoid use of doxepin hydrochloride in patients with untreated anatomically narrow angles.
Because doxepin hydrochloride can cause sedation, warn patients of the risk of sedation and caution patients against driving a car or operating dangerous machinery while taking doxepin hydrochloride. Also caution patients that their response to alcohol may be potentiated.
Sedating drugs, including doxepin hydrochloride, may cause oversedation in geriatric patients.
In patients with bipolar disorder, treating MDD with doxepin hydrochloride may precipitate a mixed/manic episode. Prior to initiating treatment with doxepin hydrochloride, screen patients for any personal or family history of bipolar disorder, mania, or hypomania. Doxepin hydrochloride is not approved for use in treating bipolar depression.
Caution should be used when doxepin hydrochloride is given to patients with a history of seizure disorder, because this drug may lower the seizure threshold. Patients with a history of seizures should be monitored during doxepin hydrochloride use to identify recurrence of seizures or increase in frequency of seizures.
In patients with schizophrenia, treatment with doxepin hydrochloride for MDD may activate psychosis. If this occurs, stop doxepin hydrochloride and consider alternative treatment options.
The following clinically significant adverse reactions are described elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse reactions (≥ 2% of doxepin hydrochloride-treated patients) in 1,635 doxepin hydrochloride-treated patients with MDD in clinical trials included somnolence (17%), dry mouth (15%), dizziness (6%), constipation (5%), fatigue (5%), blurred vision (3%), tachycardia (3%), hypotension (3%), insomnia (2%), tremor (2%), nausea (2%), hyperhidrosis (2%), and increased weight (2%).
Other Adverse Reactions Observed in Clinical Trials
Other adverse reactions that occurred at an incidence of < 2% in patients treated with doxepin hydrochloride in clinical trials were:
The following adverse reactions have been identified during post-approval use of doxepin hydrochloride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Withdrawal syndrome occurred after stopping doxepin hydrochloride [see Drug Abuse and Dependence ( 9.3 )].
The following adverse reaction has been reported with use with other tricyclic antidepressants: decreased blood glucose.
Table 2 describe the clinically significant drug interactions of doxepin hydrochloride with other drugs or classes.
Table 2: Clinically Significant Drug Interactions with Doxepin Hydrochloride
| Monoamine Oxidase Inhibitors | |
| Prevention or Management | Doxepin hydrochloride is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue. The use of doxepin hydrochloride within 14 days of discontinuation of an MAOI or the use of MAOI within 14 days of discontinuation of doxepin hydrochloride is contraindicated. Starting doxepin hydrochloride in a patient who is being treated with an MAOI is contraindicated. |
| Clinical Effect(s) | Concomitant use of doxepin hydrochloride and MAOIs increases the risk of serotonin syndrome [Warnings and Precautions (
5.2
)]. |
| Other Serotonergic Drugs (Besides MAOIs) | |
| Prevention or Management | Monitor patients for signs and symptoms of serotonin syndrome, particularly during treatment initiation and dosage increases. If serotonin syndrome occurs, consider discontinuation of doxepin hydrochloride and/or concomitant serotonergic drugs [see Warnings and Precautions (
5.2
)]. |
| Mechanism and Clinical Effect(s) | Concomitant use of doxepin hydrochloride with other serotonergic drugs increases the risk of serotonin syndrome [see Warnings and Precautions (
5.2
)]. |
| Strong CYP2D6 Inhibitors | |
| Prevention or Management | Monitor doxepin plasma concentrations and reduce the doxepin hydrochloride dosage or the strong CYP2D6 inhibitor as appropriate [see Dosage and Administration (
2.5
)]. |
| Mechanism and Clinical Effect(s) | Concomitant use of doxepin hydrochloride with strong CYP2D6 inhibitors may increase the exposures of doxepin [see Clinical Pharmacology (
12.3
)] which may increase the risk of doxepin hydrochloride related adverse reactions [see Warnings and Precautions (
5
) and Adverse Reactions (
6
)]. |
| Examples | See www.fda.gov/CYPandTransporterInteractingDrugs for examples of strong CYP2D6 Inhibitors. |
| Carbamazepine | |
| Prevention or Management | Monitor doxepin plasma concentrations and consider increasing the doxepin hydrochloride dosage in patients taking carbamazepine. |
| Mechanism and Clinical Effect(s) | Concomitant use of carbamazepine with doxepin hydrochloride decreases the exposure of doxepin [see Clinical Pharmacology (
12.3
)] which could lead to reduced treatment effect. |
| Cimetidine | |
| Prevention or Management | Monitor doxepin plasma concentrations and consider reducing the doxepin hydrochloride dosage in patients taking cimetidine. |
| Mechanism and Clinical Effect(s) | Concomitant use of doxepin hydrochloride with cimetidine may increase the exposures of doxepin [see Clinical Pharmacology (
12.3
)] which may increase the risk of doxepin hydrochloride-related anticholinergic effects (e.g., dry mouth, blurred vision, constipation) [see Adverse Reactions (
6.1
)]. |
| Alcohol | |
| Prevention or Management | Avoid concomitant use with alcohol. |
| Mechanism and Clinical Effect(s) | Doxepin hydrochloride may potentiate the sedative effects of alcohol [see Warnings and Precautions (
5.4
)]. |
| CNS Depressants | |
| Prevention or Management | Dosage reduction of doxepin hydrochloride and/or the CNS depressant may be needed based on clinical response and tolerability. |
| Mechanism and Clinical Effect(s) | When concomitantly administered with doxepin hydrochloride, the sedative effects of CNS depressant may be potentiated [see Warnings and Precautions (
5.4
)]. |
| Tolazamide | |
| Prevention or Management | Monitor glucose levels and reduce the doxepin hydrochloride dosage as appropriate. |
| Clinical Effect(s) | Doxepin hydrochloride may cause severe hypoglycemia when concomitantly used with tolazamide. |
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including doxepin hydrochloride, during pregnancy. Healthcare providers are encouraged to advise patients to register by calling the National Pregnancy Registry for Antidepressants 1-866-961-2388 or visiting online at womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants
programs/pregnancyregistry/antidepressants.
Risk Summary
Available data from published epidemiological studies and postmarketing reports have not established an increased risk for major birth defects or miscarriage with doxepin hydrochloride use (see
Data
). There are risks (see
Clinical Considerations
):
Animal reproduction toxicity of doxepin has not been fully characterized.
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations
Disease-associated Maternal and/or Embryofetal Risk
Women who discontinue antidepressants during pregnancy are more likely to experience a relapse of MDD than women who continue antidepressants. This finding is from a prospective longitudinal study of 201 pregnant women with a history of MDD who were euthymic and taking antidepressants at the beginning of pregnancy. Consider the risk of untreated MDD when considering discontinuation of doxepin hydrochloride drugs during pregnancy and the postpartum period.
Fetal/Neonatal Adverse Reactions
Neonates previously exposed to TCAs, including doxepin hydrochloride, late in the third trimester during pregnancy have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These findings are consistent with either direct toxic effects of TCAs or possibly a drug discontinuation syndrome. Monitor neonates who were exposed to doxepin hydrochloride in the third trimester of pregnancy for poor neonatal adaptation syndrome.
Data
Human Data: Published epidemiological studies of pregnant women exposed to TCAs, including doxepin hydrochloride, have not established an association with major birth defects, miscarriage, or adverse maternal outcomes. Methodological limitations of these observational studies include small sample size and lack of adequate controls.
Risk Summary
Data from published literature report the presence of doxepin and nordoxepin in human milk. There are reports of excessive sedation, respiratory depression, poor suckling and swallowing and hypotonia in breastfed infants exposed to doxepin at doses used to treat MDD. There are no data on the effects of doxepin on milk production.
Because of the potential for serious adverse reactions, including excess sedation and respiratory depression in a breastfed infant, advise patients that breastfeeding is not recommended during doxepin hydrochloride treatment.
The safety and effectiveness of doxepin hydrochloride in pediatric patients have not been established.
Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric patients [see Warnings and Precautions ( 5.1 )].
Clinical studies of doxepin hydrochloride did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.
Sedating drugs, including doxepin hydrochloride, may cause confusion and oversedation in geriatric patients. The recommended starting doxepin hydrochloride dosage in geriatric patients is generally lower than those of younger adult patients.
The effect of hepatic impairment (HI) on the pharmacokinetics of doxepin has not been studied. Doxepin is primarily metabolized in the liver. Doxepin hydrochloride-treated patients with HI may have a greater systemic doxepin exposure than those with normal liver function. Consider obtaining doxepin concentrations in patients with HI and modifying the dosage as appropriate.
The recommended doxepin hydrochloride dosage in CYP2C19 and CYP2D6 poor metabolizers is lower than the recommended dosage in CYP2C19 and CYP2D6 normal metabolizers [see Dosage and Administration ( 2.6 )].
According to the literature, doxepin is primarily metabolized by CYP2D6 and/or CYP2C19; thus, the use of doxepin hydrochloride in CYP2D6 and/or CYP2C19 poor metabolizers will likely result in higher doxepin exposures and an increased risk of doxepin hydrochloride-associated adverse reactions.
Doxepin hydrochloride contains doxepin, which is not a controlled substance.
Doxepin hydrochloride is not associated with abuse.
Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Abrupt cessation of doxepin hydrochloride after prolonged administration can result in withdrawal symptoms, which is indicative of physical dependence.
Signs, Symptoms, and Complications of Doxepin Hydrochloride Overdose
Serious manifestations of tricyclic antidepressant (TCA) overdose include cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression, including coma. Deaths may occur from overdosage with TCAs, including doxepin hydrochloride. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of TCA toxicity. A maximal limb-lead QRS duration of ≥ 0.1 seconds may be the best indication of the TCA overdose severity.
Signs and symptoms of TCA toxicity develop rapidly after TCA overdose. Other signs of TCA overdose may include confusion, disturbed concentration, transient visual hallucinations, dilated pupils, agitation, hyperactive reflexes, stupor, drowsiness, muscle rigidity, vomiting, hypothermia, or hyperpyrexia. There are reports of patients succumbing to fatal dysrhythmia late after TCA overdose.
Management of Overdose
The following are recommendations for the management of a doxepin hydrochloride overdose. Contact the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.
With a doxepin hydrochloride overdose, obtain an ECG and immediately initiate cardiac monitoring in the hospital. A minimum of six hours of observation with cardiac monitoring and observation for signs of CNS depression, respiratory depression, hypotension, cardiac dysrhythmias, conduction blocks, and seizures is recommended. If signs of toxicity occur during this period, extended monitoring is recommended.
Monitoring of plasma doxepin levels should not guide doxepin hydrochloride overdose management.
Cardiovascular Toxicity Management: Intravenous sodium bicarbonate should be administered to maintain the serum pH in the range of 7.45 to 7.55. If the pH response is inadequate to intravenous sodium bicarbonate therapy, hyperventilation may also be used. With concomitant use of hyperventilation and sodium bicarbonate therapy frequently monitor pH and pCO2. A pH > 7.6 or a pCO2 < 20 mm Hg is undesirable. Dysrhythmias unresponsive to intravenous sodium bicarbonate therapy/hyperventilation may respond to lidocaine therapy. Type 1A and 1C antiarrhythmics are generally contraindicated (e.g., quinidine, disopyramide, and procainamide) in the setting of TCA overdose. Hemodialysis, peritoneal dialysis, exchange transfusions, and forced diuresis generally have been reported as ineffective in TCA overdose due to high tissue and protein binding of doxepin.
CNS Toxicity Management: In patients with TCA overdose who have CNS depression, early intubation is recommended because of the potential for abrupt deterioration. Seizures should be controlled with benzodiazepines, or if these are ineffective, other anticonvulsants (e.g., phenobarbital, propofol). Avoid use of physostigmine to treat TCA overdose.
Doxepin is a tricyclic antidepressant.
The molecular formula of doxepin hydrochloride is C19H21NO·HCl with a molecular weight of 315.84. It is a white crystalline solid soluble in water, lower alcohols and chloroform. Doxepin is a dibenzoxepin derivative. Specifically, it is an isomeric mixture of:
1-Propanamine, 3-dibenz[b,e]oxepin-11(6H)ylidene-N,N-dimethyl-, hydrochloride. The structural formula of doxepin is shown below.
doxepin hydrochloride
Doxepin Hydrochloride Oral Solution USP is available as a concentrate for oral administration containing doxepin hydrochloride equivalent to 10 mg of doxepin per mL. It also contains the following inactive ingredients: glycerin; methylparaben; peppermint flavor; propylparaben; water. May contain hydrochloric acid and/or sodium hydroxide.
The mechanism of action of the doxepin hydrochloride in the treatment of MDD in adult patients is not well understood.
The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of doxepin have not been fully characterized.
Absorption
In healthy volunteers, a single oral doxepin hydrochloride dose of 75 mg resulted in peak plasma doxepin concentrations that ranged from 8.8 ng/mL to 45.8 ng/mL (mean 26.1 ng/mL). Peak levels were reached between 2 and 4 hours (mean 2.9 hours) after doxepin hydrochloride administration. Peak levels for the primary active metabolite N-desmethyldoxepin (nordoxepin) ranged from 4.8 ng/mL to 14.5 ng/mL (mean 9.7 ng/mL) and were achieved between 2 and 10 hours after doxepin hydrochloride administration.
Distribution
The mean apparent volume of distribution for doxepin was approximately 20 L/kg. The protein binding for doxepin was approximately 76%.
Elimination
In healthy volunteers, the plasma elimination half-life of doxepin ranged from 8 to 24 hours (mean 17 hours). The half-life of nordoxepin ranged from 33 to 80 hours (mean 51 hours). The mean plasma clearance for doxepin was approximately 0.84 L/hour/kg.
Metabolism
After oral doxepin hydrochloride administration, approximately 55% to 87% of doxepin undergoes first-pass metabolism in the liver, forming the primary active metabolite nordoxepin. Metabolic pathways of doxepin include demethylation, N-oxidation, hydroxylation and glucuronide formation.
Excretion
Doxepin is excreted primarily in the urine, mainly as its metabolites, either free or in conjugate form.
Specific Populations
Patients with Hepatic Impairment: Specific clinical studies have not been performed to evaluate the pharmacokinetics of doxepin in patients with hepatic impairment. Patients with hepatic impairment may have a greater systemic doxepin exposure than those with normal liver function [see Use in Specific Populations (8.6)].
Patients with Renal Impairment: The extent of renal excretion of doxepin is unknown. Specific clinical studies have not been performed to evaluate the pharmacokinetics of doxepin in patients with renal impairment compared to those with normal renal function.
Drug Interaction Studies
Carbamazepine: After concomitant use of doxepin hydrochloride and carbamazepine, the combined exposure of doxepin and nordoxepin (12 hours after the last dose) was decreased by 55% compared to that after the use of doxepin hydrochloride alone [see Drug Interactions (
7
)].
Strong CYP2D6 Inhibitors: CYP2D6 contributes to the metabolism of doxepin and concomitant use of doxepin hydrochloride with strong CYP2D6 inhibitors may increase doxepin exposure [see Drug Interactions ( 7 )].
Cimetidine: Cimetidine is a non-specific inhibitor of CYP1A2, 2C19, 2D6, and 3A4. When cimetidine 300 mg twice daily was administered concomitantly with a single 6 mg dose of another oral doxepin product, there was approximately a 2-fold increase in doxepin Cmax and AUC compared to doxepin without cimetidine [see Drug Interactions ( 7 )].
CYP2D6 Substrates: Concomitant use of doxepin hydrochloride and other CYP2D6 substrates may have impact on the plasma doxepin concentrations. The clinical significance of this possible impact is unknown.
Carcinogenesis
The carcinogenic potential of doxepin in animals has not been fully characterized.
Mutagenesis
The mutagenetic potential of doxepin in animals has not been fully characterized.
Impairment of Fertility
Doxepin had no effect on female fertility in rats at oral doses up to 25 mg/kg/day (1.6x the human dose of 150 mg/day on a mg/m2 basis for a 60 kg human).
Insemination and conception were reduced in untreated female rats mated with male rats administered doxepin at 25 mg/kg/day for a period of ≥ 7 months.
How Supplied
Doxepin Hydrochloride Oral Solution USP (Concentrate). Each mL of oral solution contains 10 mg of doxepin as a clear, colorless solution and is supplied in 120 mL bottles (NDC 54838-512-40) with an accompanying dropper calibrated at 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg.
Store Doxepin Hydrochloride Oral Solution USP at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].
Advise patients to read FDA-approved patient labeling (Medication Guide).
Suicidal Thoughts and Behaviors
Advise patients and caregivers to look for the emergence of suicidal thoughts and behaviors, especially early during doxepin hydrochloride treatment and when the dosage is increased or decreased, and instruct them to report suicidal thinking and behavior to their healthcare provider [see Warnings and Precautions (
5.1
)].
Serotonin Syndrome
Caution patients about the risk of serotonin syndrome particularly with the concomitant use of doxepin hydrochloride and other serotonergic drugs (e.g., other TCAs, SSRIs, SNRIs, triptans, opioids), lithium, tryptophan, buspirone, and St. John’s Wort and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid) [see Warnings and Precautions (
5.2
), Drug Interactions (
7
)]. Instruct patients to contact their healthcare provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome.
Angle-Closure Glaucoma
Advise patients that taking doxepin hydrochloride can cause pupillary dilation, which in susceptible individuals, can trigger angle closure glaucoma. Patients may wish to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible [see Warnings and Precautions (
5.3
)].
Effects on Driving and Operating Heavy Machinery
Inform patients that doxepin hydrochloride can cause sedation and caution them against driving a car or operating dangerous machinery while taking doxepin hydrochloride [see Warnings and Precautions (
5.4
)].
Activation of Mania or Hypomania
Advise patients to observe for signs of mania/hypomania activation and instruct them to report such symptoms to the healthcare provider.
Drug Interactions
Inform patients that the use of doxepin hydrochloride and certain other drugs increases the risk of doxepin hydrochloride-associated adverse reactions or alternatively lower doxepin hydrochloride effectiveness. Instruct patients to inform their healthcare provider about all the drugs that they are taking before taking doxepin hydrochloride.
Alcohol Use
Advise patients to avoid the use of alcohol while taking doxepin hydrochloride [see Drug Interactions (
7
)].
Pregnancy
Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to doxepin hydrochloride during pregnancy. Advise women to notify their healthcare provider if they become pregnant or intend to become pregnant during doxepin hydrochloride treatment.
Advise pregnant women that doxepin hydrochloride use late in pregnancy may increase the risk for neonatal complications requiring prolonged hospitalization, respiratory support, or tube feeding [see Use in Specific Populations ( 8.1 )].
Lactation
Advise patients that breastfeeding is not recommended during doxepin hydrochloride treatment [see Use in Specific Populations (
8.2
)].
Important Administration Instructions for the Oral Solution
For patients prescribed Doxepin Hydrochloride Oral Solution, tell them to:
Distributed by:
Lannett Company, Inc.
Philadelphia, PA 19136
This product’s labeling may have been updated. For the most recent Prescribing Information, please visit www.lannett.com.
CIB72247B
Rev. 09/2026
Doxepin Hydrochloride |
What is the most important information I should know about doxepin hydrochloride? Doxepin hydrochloride can cause serious side effects, including: Increased risk of suicidal thoughts and actions. Doxepin hydrochloride and other antidepressant medicines may increase the risk of suicidal thoughts and actions in people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed. Doxepin hydrochloride is not for use in children. How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?
Call your healthcare provider or get emergency help right away if you or a family member have any of the following symptoms, especially if they are new, worse, or worry you:
|
What is doxepin hydrochloride? Doxepin hydrochloride is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder (MDD). It is not known if doxepin hydrochloride is safe and effective for use in children. |
Do not take doxepin hydrochloride if you:
|
Before taking doxepin hydrochloride, tell your healthcare provider about all your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Doxepin hydrochloride and other medicines may affect each other causing possible serious side effects. Doxepin hydrochloride may affect the way other medicines work and other medicines may affect the way doxepin hydrochloride works. Especially tell your healthcare provider if you take:
Ask your healthcare provider if you are not sure if you are taking any of these medicines. Your healthcare provider can tell you if it is safe to take doxepin hydrochloride with your other medicines. Do not start or stop any other medicines during treatment with doxepin hydrochloride without first talking to your healthcare provider. Know the medicines you take. Keep a list of them to show to your healthcare providers when you start to take a new medicine. |
How should I take doxepin hydrochloride?
|
What should I avoid while taking doxepin hydrochloride?
|
What are the possible side effects of doxepin hydrochloride? Doxepin hydrochloride can cause serious side effects, including:
The most common side effects of doxepin hydrochloride include:
These are not all the possible side effects of doxepin hydrochloride. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
How should I store doxepin hydrochloride?
|
General Information about the safe and effective use of doxepin hydrochloride. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not take doxepin hydrochloride for a condition for which it was not prescribed. Do not give doxepin hydrochloride to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about doxepin hydrochloride that is written for health professionals. |
What are the ingredients in doxepin hydrochloride? Active ingredient: doxepin hydrochloride Inactive Ingredients for Doxepin Hydrochloride Oral Solution: glycerin; methylparaben; peppermint flavor; propylparaben; water. May contain hydrochloric acid and/or sodium hydroxide. Distributed by: www.lannett.com. |
This Medication Guide has been approved by the U.S. Food and Drug Administration.
CIB72248B
Rev. 09/2026
NDC 54838-512-40
Doxepin
Hydrochloride
Oral Solution USP
(Concentrate)
equivalent to
10 mg per mL
of doxepin
Rx Only
120 mL
Lannett
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | EAN-13 | 0354838512403 | GTIN-13: 0354838512403 EAN-13: 0354838512403 GTIN-12: 354838512403 UPC-A: 354838512403 GTIN storage (14 digits): 00354838512403 | doxepin-hydrochloride-solution-2.jpg |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| f6fcd62d-384f-5faa-05d7-c5d5903c6c43 | Product name | 4 | 20250515 |
| 3d5463a5-d368-9c2b-b40c-0f2b688e406e | Product name | 9 | 20240805 |
| 750bc85a-c69c-4145-a865-3f1124677d16 | Product name | 3 | 20240321 |
| eda77195-5c17-5c7f-a6a7-8c80d2f8ae5f | Product name | 1 | 20140508 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 54838-512-40 | ML - Milliliter | 54838-512 | fb35cab2-5298-495b-8078-afadb3d0e83a | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Doxepin Hydrochloride | ACTIVE INGREDIENT | 3U9A0FE9N5 | 15 | |
| Doxepin | ACTIVE MOIETY | 5ASJ6HUZ7D | 15 | |
| glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 15 | |
| hydrochloric acid | INACTIVE INGREDIENT | QTT17582CB | 15 | |
| methylparaben | INACTIVE INGREDIENT | A2I8C7HI9T | 15 | |
| propylparaben | INACTIVE INGREDIENT | Z8IX2SC1OH | 15 | |
| sodium hydroxide | INACTIVE INGREDIENT | 55X04QC32I | 15 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 15 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 54838-512 | 54838-512-40 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| DOXEPIN HYDROCHLORIDE | 3U9A0FE9N5 | ACTIM |
| GLYCERIN | PDC6A3C0OX | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
| HYDROCHLORIC ACID | QTT17582CB | IACT |
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 24 | 2025-07-16 | full-release | 2026-05-31 21:42:30 |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / ORAL | 100 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / ORAL | 9120 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / ORAL | 223 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SOLUTION / ORAL | 346 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SOLUTION / ORAL | 346 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / ORAL | 100 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / ORAL | 223 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / ORAL | 9120 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A074721-001 | DOXEPIN HYDROCHLORIDE | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | RS | 1998-12-29 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | RS | 1998-12-29 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | RS | 1998-12-29 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | 1998-12-29 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | RS | 1998-12-29 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | RS | 1998-12-29 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | RS | 1998-12-29 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | RS | 1998-12-29 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | RS | 1998-12-29 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | RS | 1998-12-29 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | 1998-12-29 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | 1998-12-29 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | 1998-12-29 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | RS | 1998-12-29 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | RS | 1998-12-29 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | RS | 1998-12-29 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | RS | 1998-12-29 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | RS | 1998-12-29 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | RS | 1998-12-29 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A074721-001 | DOXEPIN HYDROCHLORIDE | EQ 10MG BASE/ML | CONCENTRATE / ORAL | AA | RS | 1998-12-29 | f41ea6bd6efb… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A074721-001 | AA | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A074721-001 | AA | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A074721-001 | AA | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A074721-001 | AA | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A074721-001 | AA | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A074721-001 | AA | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A074721-001 | AA | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A074721-001 | AA | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A074721-001 | AA | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A074721-001 | AA | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A074721-001 | AA | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A074721-001 | AA | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A074721-001 | AA | 1 | ea99ee380514… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A074721-001 | AA | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A074721-001 | AA | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A074721-001 | AA | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A074721-001 | AA | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A074721-001 | AA | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A074721-001 | AA | 1 | f41ea6bd6efb… |
| 2022-09-29 23:25 UTC | 2022-09 | A074721-001 | AA | 1 | e64feba35796… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A074721-001 | AA | 1 | cb3db0bc1861… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 5408fdf5-16a7-4d5a-b4c4-2ccb271759a2 | f350afed-120b-422d-9e6e-3aaa0f72a5fb | 2025-07-16 | Boxed warning, Warnings, Adverse reactions | f350afed-120b-422d-9e6e-3aaa0f72a5fb |
Adverse event summaries are temporarily unavailable. Other product information remains available.